Anavex Life Sciences Corp (AVXL)

[DoubleJ23]

For any others like me who are watching the patent information closely, I want to draw your attention to slide 11 "ANAVEX 2-73 also shows synergistic activity with three generations of epilepsy drugs currently on the
market: ETS (Zarontin®), VPA (Depakene®) and Gabapentin (Neurontin®)"

Angelman Presentation

If AVXL is going to pursue a combo patent here, they could follow a similar process as with the Plus patent. By demonstrating SYNERGY, the FDA should allow them to patent the combinations.